

# Daniel I Prez

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8030672/daniel-i-perez-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

49  
papers

1,901  
citations

26  
h-index

43  
g-index

53  
ext. papers

2,127  
ext. citations

6.1  
avg, IF

4.5  
L-index

#	Paper	IF	Citations
49	GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease?. <i>Journal of Alzheimer's Disease</i> , <b>2008</b> , 15, 181-91	4.3	105
48	Visible light-driven and chloroperoxidase-catalyzed oxygenation reactions. <i>Chemical Communications</i> , <b>2009</b> , 6848-50	5.8	103
47	Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases. <i>Medicinal Research Reviews</i> , <b>2011</b> , 31, 924-54	14.4	98
46	Thienyl and phenyl alpha-halomethyl ketones: new inhibitors of glycogen synthase kinase (GSK-3beta) from a library of compound searching. <i>Journal of Medicinal Chemistry</i> , <b>2003</b> , 46, 4631-3	8.3	92
45	Multitarget drug discovery for Alzheimer's disease: triazinones as BACE-1 and GSK-3 inhibitors. <i>Angewandte Chemie - International Edition</i> , <b>2015</b> , 54, 1578-82	16.4	87
44	Exploring the binding sites of glycogen synthase kinase 3. Identification and characterization of allosteric modulation cavities. <i>Journal of Medicinal Chemistry</i> , <b>2011</b> , 54, 8461-70	8.3	78
43	Versatility of the Curcumin Scaffold: Discovery of Potent and Balanced Dual BACE-1 and GSK-3 inhibitors. <i>Journal of Medicinal Chemistry</i> , <b>2016</b> , 59, 531-44	8.3	73
42	Immobilization of horseradish peroxidase as crosslinked enzyme aggregates (CLEAs). <i>Process Biochemistry</i> , <b>2011</b> , 46, 765-769	4.8	72
41	Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis. <i>Journal of Medicinal Chemistry</i> , <b>2014</b> , 57, 2755-72	8.3	70
40	Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2013</b> , 34, 2133-45	5.6	64
39	5-imino-1,2,4-thiadiazoles: first small molecules as substrate competitive inhibitors of glycogen synthase kinase 3. <i>Journal of Medicinal Chemistry</i> , <b>2012</b> , 55, 1645-61	8.3	61
38	Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer's disease treatment. <i>International Journal of Alzheimer's Disease</i> , <b>2011</b> , 2011, 280502	3.7	60
37	Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: clues for specific design of new compounds. <i>Journal of Medicinal Chemistry</i> , <b>2011</b> , 54, 4042-56	8.3	60
36	Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model. <i>European Journal of Medicinal Chemistry</i> , <b>2012</b> , 47, 175-85	6.8	53
35	PDE 7 inhibitors: new potential drugs for the therapy of spinal cord injury. <i>PLoS ONE</i> , <b>2011</b> , 6, e15937	3.7	52
34	3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the First Dual BACE-1/GSK-3 Fragment Hits against Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , <b>2015</b> , 6, 1665-82	5.7	47
33	Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease. <i>ACS Chemical Neuroscience</i> , <b>2013</b> , 4, 350-60	5.7	47

32	Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin. <i>European Journal of Medicinal Chemistry</i> , <b>2013</b> , 60, 479-89	6.8	47
31	Thienylhalomethylketones: Irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools. <i>Bioorganic and Medicinal Chemistry</i> , <b>2009</b> , 17, 6914-25	3.4	44
30	Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds. <i>Journal of Medicinal Chemistry</i> , <b>2012</b> , 55, 3274-84	8.3	43
29	Targeting TDP-43 phosphorylation by Casein Kinase-1 inhibitors: a novel strategy for the treatment of frontotemporal dementia. <i>Molecular Neurodegeneration</i> , <b>2016</b> , 11, 36	19	37
28	PDE7 inhibitors as new drugs for neurological and inflammatory disorders. <i>Expert Opinion on Therapeutic Patents</i> , <b>2008</b> , 18, 1127-1139	6.8	37
27	Subtly Modulating Glycogen Synthase Kinase 3 Allosteric Inhibitor Development and Their Potential for the Treatment of Chronic Diseases. <i>Journal of Medicinal Chemistry</i> , <b>2017</b> , 60, 4983-5001	8.3	36
26	A Fluorescent Styrylquinoline with Combined Therapeutic and Diagnostic Activities against Alzheimer's and Prion Diseases. <i>ACS Medicinal Chemistry Letters</i> , <b>2013</b> , 4, 225-9	4.3	36
25	Cross-Linked Enzyme Aggregates of Chloroperoxidase: Synthesis, Optimization and Characterization. <i>Advanced Synthesis and Catalysis</i> , <b>2009</b> , 351, 2133-2139	5.6	36
24	Lessons learnt from glycogen synthase kinase 3 inhibitors development for Alzheimer's disease. <i>Current Topics in Medicinal Chemistry</i> , <b>2013</b> , 13, 1808-19	3	28
23	In Vitro Inhibitory Effects of 8-O-Demethylmaritidine and Undulatine on Acetylcholinesterase and Their Predicted Penetration across the Blood-Brain Barrier. <i>Journal of Natural Products</i> , <b>2015</b> , 78, 1189-92	4.9	24
22	The potential role of glycogen synthase kinase 3 inhibitors as amyotrophic lateral sclerosis pharmacological therapy. <i>Current Medicinal Chemistry</i> , <b>2011</b> , 18, 3028-34	4.3	24
21	Application of BACE1 immobilized enzyme reactor for the characterization of multifunctional alkaloids from <i>Corydalis cava</i> (Fumariaceae) as Alzheimer's disease targets. <i>Fluoterap</i> , <b>2016</b> , 109, 241-7	3.2	23
20	A small chemical library of 2-aminoimidazole derivatives as BACE-1 inhibitors: Structure-based design, synthesis, and biological evaluation. <i>European Journal of Medicinal Chemistry</i> , <b>2012</b> , 48, 206-13	6.8	22
19	An application of two MIFs-based tools (Volsurf+ and Pentacle) to binary QSAR: the case of a palinurin-related data set of non-ATP competitive glycogen synthase kinase 3 (GSK-3) inhibitors. <i>European Journal of Medicinal Chemistry</i> , <b>2011</b> , 46, 860-9	6.8	22
18	The first enantioselective synthesis of palinurin. <i>Chemical Communications</i> , <b>2009</b> , 3252-4	5.8	22
17	5-Imino-1,2,4-thiadiazoles and quinazolines derivatives as glycogen synthase kinase 3 (GSK-3) and phosphodiesterase 7 (PDE7) inhibitors: determination of blood-brain barrier penetration and binding to human serum albumin. <i>European Journal of Pharmaceutical Sciences</i> , <b>2012</b> , 45, 677-84	5.1	20
16	1-(Benzo[d]thiazol-2-yl)-3-phenylureas as dual inhibitors of casein kinase 1 and ABAD enzymes for treatment of neurodegenerative disorders. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , <b>2018</b> , 33, 665-670	5.6	18
15	Modulation of cAMP-specific PDE without emetogenic activity: new sulfide-like PDE7 inhibitors. <i>Journal of Medicinal Chemistry</i> , <b>2014</b> , 57, 8590-607	8.3	18

14	Identification in silico and experimental validation of novel phosphodiesterase 7 inhibitors with efficacy in experimental autoimmune encephalomyelitis mice. <i>ACS Chemical Neuroscience</i> , <b>2012</b> , 3, 793-803	5.7	18
13	From Bitopic Inhibitors to Multitarget Drugs for the Future Treatment of Alzheimer's Disease. <i>Current Medicinal Chemistry</i> , <b>2015</b> , 22, 3789-806	4.3	18
12	A Triazolotriazine-Based Dual GSK-3/CK-1 Ligand as a Potential Neuroprotective Agent Presenting Two Different Mechanisms of Enzymatic Inhibition. <i>ChemMedChem</i> , <b>2019</b> , 14, 310-314	3.7	16
11	In Vitro and In Silico Acetylcholinesterase Inhibitory Activity of Thalictricavine and Canadine and Their Predicted Penetration across the Blood-Brain Barrier. <i>Molecules</i> , <b>2019</b> , 24,	4.8	13
10	Microwave-assisted synthesis of hydroxyphenyl nitrones with protective action against oxidative stress. <i>European Journal of Medicinal Chemistry</i> , <b>2012</b> , 58, 44-9	6.8	13
9	Small GSK-3 Inhibitor Shows Efficacy in a Motor Neuron Disease Murine Model Modulating Autophagy. <i>PLoS ONE</i> , <b>2016</b> , 11, e0162723	3.7	10
8	Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosis. <i>European Journal of Medicinal Chemistry</i> , <b>2021</b> , 210, 112968	6.8	9
7	Computer-aided molecular design of pyrazolotriazines targeting glycogen synthase kinase 3. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , <b>2019</b> , 34, 87-96	5.6	8
6	New applications for known drugs: Human glycogen synthase kinase 3 inhibitors as modulators of <i>Aspergillus fumigatus</i> growth. <i>European Journal of Medicinal Chemistry</i> , <b>2016</b> , 116, 281-289	6.8	7
5	Biological and Pharmacological Characterization of Benzothiazole-Based CK-1 Inhibitors in Models of Parkinson's Disease. <i>ACS Omega</i> , <b>2017</b> , 2, 5215-5220	3.9	7
4	Improved Controlled Release and Brain Penetration of the Small Molecule S14 Using PLGA Nanoparticles. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	7
3	Increasing Brain Permeability of PHA-767491, a Cell Division Cycle 7 Kinase Inhibitor, with Biodegradable Polymeric Nanoparticles. <i>Pharmaceutics</i> , <b>2021</b> , 13,	6.4	7
2	Multitarget Drug Discovery for Alzheimer's Disease: Triazinones as BACE-1 and GSK-3 Inhibitors. <i>Angewandte Chemie</i> , <b>2015</b> , 127, 1598-1602	3.6	5
1	Developing novel classes of protein kinase CK1 Inhibitors by fusing [1,2,4]triazole with different bicyclic heteroaromatic systems. <i>European Journal of Medicinal Chemistry</i> , <b>2021</b> , 216, 113331	6.8	3